TrialAmerican journal of hematology2021

A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).

Peter M Voorhees et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.